Cargando…

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C

BACKGROUND AND AIM: Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colombo, M, Fernández, I, Abdurakhmanov, D, Ferreira, P A, Strasser, S I, Urbanek, P, Moreno, C, Streinu-Cercel, A, Verheyen, A, Iraqi, W, DeMasi, R, Hill, A, Läuffer, J M, Lonjon-Domanec, I, Wedemeyer, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078754/ https://www.ncbi.nlm.nih.gov/pubmed/24201995 http://dx.doi.org/10.1136/gutjnl-2013-305667

Ejemplares similares

Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis
por: Lepida, Antonia, et al.
Publicado: (2015)

Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Romania
por: Streinu-Cercel, Adrian, et al.
Publicado: (2013)

Management and outcomes of side effects with focus on anaemia in patients with hepatitis C genotype 1 infection: the telaprevir early access program in patients from Romania
por: Streinu-Cercel, Adrian, et al.
Publicado: (2013)

Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2013)

Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection
por: Aliabadi, Elmira, et al.
Publicado: (2022)

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
por: Van, Nguyen Dinh, et al.
Publicado: (2016)

Dysregulated activation of fetal liver programme in acute liver failure
por: Hyun, Jeongeun, et al.
Publicado: (2019)

In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome
por: Todt, Daniel, et al.
Publicado: (2016)

Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8(+) T cells
por: Winkler, Frances, et al.
Publicado: (2023)

Telaprevir
Publicado: (2012)

Challenges of continuation of live liver donor programme during COVID-19 pandemic in Pakistan: outcomes and lessons learned
por: Dogar, Abdul Wahab, et al.
Publicado: (2021)

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
por: Burm, Rani, et al.
Publicado: (2023)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

STAT4-associated natural killer cell tolerance following liver transplantation
por: Jamil, K M, et al.
Publicado: (2017)

Aflatoxin B(1) exposure and liver cirrhosis in Guatemala: a case–control study
por: Alvarez, Christian S, et al.
Publicado: (2020)

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia
por: Maev, Igor V, et al.
Publicado: (2020)

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss
por: Hallsworth, Kate, et al.
Publicado: (2011)

Nonalcoholic fatty liver disease burden: Australia, 2019–2030
por: Adams, Leon A, et al.
Publicado: (2020)

Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects
por: Kechagias, S, et al.
Publicado: (2008)

Effect of COVID-19 on presentations of decompensated liver disease in Scotland
por: Manship, Thomas, et al.
Publicado: (2022)

Fragile X mental retardation protein protects against tumour necrosis factor-mediated cell death and liver injury
por: Zhuang, Yuan, et al.
Publicado: (2020)

Trends in indirect liver function marker testing in Wales from 2000 to 2017 and their association with age and sex: an observational study
por: Hill, Trevor Alexander, et al.
Publicado: (2022)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Prolonged dual hypothermic oxygenated machine preservation (DHOPE-PRO) in liver transplantation: study protocol for a stage 2, prospective, dual-arm, safety and feasibility clinical trial
por: Brüggenwirth, Isabel M A, et al.
Publicado: (2022)

Pleiotrophin regulates the ductular reaction by controlling the migration of cells in liver progenitor niches
por: Michelotti, Gregory A, et al.
Publicado: (2016)

GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity
por: Ruffolo, Luis I, et al.
Publicado: (2022)

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
por: Pinyol, Roser, et al.
Publicado: (2019)

Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study
por: Robaeys, Geert, et al.
Publicado: (2017)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection
por: Murata, Kazumoto, et al.
Publicado: (2018)

Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes
por: Mengshol, J A, et al.
Publicado: (2009)

Managing hepatic complications of pregnancy: practical strategies for clinicians
por: Morrison, Maura Alice, et al.
Publicado: (2022)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study
por: Tincopa, Monica A, et al.
Publicado: (2021)

Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies
por: Middleton, Paul, et al.
Publicado: (2021)

Prevalence and trends of transfusion transmissible infections among blood donors in Basra, Iraq
por: Mohammed, Khairallah A S, et al.
Publicado: (2023)

Unexpected clinical outcomes following the implementation of a standardised order set for hepatic encephalopathy
por: KC, Mandip, et al.
Publicado: (2021)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH)
por: Chawla, Kashmira S, et al.
Publicado: (2016)

Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux
por: Crouchet, Emilie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_po4rqontvqutp720voatl4jpqu